Abstract:BackgroundJaundice is a common symptom of inherited or acquired liver diseases or a manifestation of diseases involving red blood cell metabolism. Recent progress has elucidated the molecular mechanisms of bile metabolism, hepatocellular transport, bile ductular development, intestinal bile salt reabsorption, and the regulation of bile acids homeostasis.Main bodyThe major genetic diseases causing jaundice involve disturbances of bile flow. The insufficiency of bile salts in the intestines leads to fat malabsorption and fat-soluble vitamin deficiencies. Accumulation of excessive bile acids and aberrant metabolites results in hepatocellular injury and biliary cirrhosis. Progressive familial intrahepatic cholestasis (PFIC) is the prototype of genetic liver diseases manifesting jaundice in early childhood, progressive liver fibrosis/cirrhosis, and failure to thrive. The first three types of PFICs identified (PFIC1, PFIC2, and PFIC3) represent defects in FIC1 (ATP8B1), BSEP (ABCB11), or MDR3 (ABCB4). In the last 5 years, new genetic disorders, such as TJP2, FXR, and MYO5B defects, have been demonstrated to cause a similar PFIC phenotype. Inborn errors of bile acid metabolism also cause progressive cholestatic liver injuries. Prompt differential diagnosis is important because oral primary bile acid replacement may effectively reverse liver failure and restore liver functions. DCDC2 is a newly identified genetic disorder causing neonatal sclerosing cholangitis. Other cholestatic genetic disorders may have extra-hepatic manifestations, such as developmental disorders causing ductal plate malformation (Alagille syndrome, polycystic liver/kidney diseases), mitochondrial hepatopathy, and endocrine or chromosomal disorders. The diagnosis of genetic liver diseases has evolved from direct sequencing of a single gene to panel-based next generation sequencing. Whole exome sequencing and whole genome sequencing have been actively investigated in research and clinical studies. Current treatment modalities include medical treatment (ursodeoxycholic acid, cholic acid or chenodeoxycholic acid), surgery (partial biliary diversion and liver transplantation), symptomatic treatment for pruritus, and nutritional therapy. New drug development based on gene-specific treatments, such as apical sodium-dependent bile acid transporter (ASBT) inhibitor, for BSEP defects are underway.Short conclusionUnderstanding the complex pathways of jaundice and cholestasis not only enhance insights into liver pathophysiology but also elucidate many causes of genetic liver diseases and promote the development of novel treatments.

Progressive Familial Intrahepatic Cholestasis Related to Mutation of the TJP2 Gene: Recent Advances

Novel Compound Heterozygote Mutations of TJP2 in a Chinese Child with Progressive Cholestatic Liver Disease

Two Novel Pathogenic Variants of <i>TJP2</i> Gene and the Underlying Molecular Mechanisms in Progressive Familial Intrahepatic Cholestasis Type 4 Patients

Two Novel Pathogenic Variants of TJP2 Gene and the Underlying Molecular Mechanisms in Progressive Familial Intrahepatic Cholestasis Type 4 Patients

Advances in the Study of Familial Intrahepatic Cholestasis

TJP2 Hepatobiliary Disorders: Novel Variants and Clinical Diversity

Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases

Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis

Low-GGT Intrahepatic Cholestasis Associated with Biallelic USP53 Variants: Clinical, Histological and Ultrastructural Characterization

Genetic alterations and molecular mechanisms underlying hereditary intrahepatic cholestasis

[Clinical and Genetic Analysis of a Family Affected by Progressive Familial Intraphepatic Cholestasis Type 3].

Genetic diagnosis of progressive familial intrahepatic cholestasis type 2

Expanding the spectrum of progressive familial intrahepatic cholestasis: A report of 3 cases

Expanding etiology of progressive familial intrahepatic cholestasis

Protective Functions of ZO-2/Tjp2 Expressed in Hepatocytes and Cholangiocytes Against Liver Injury and Cholestasis

Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency

Clinical symptoms, biochemistry, and liver histology during the native liver period of progressive familial intrahepatic cholestasis type 2

Familial intrahepatic cholestasis: New and wide perspectives

Progressive familial intrahepatic cholestasis type 4: a case report

Molecular Findings in Children with Inherited Intrahepatic Cholestasis

Current Research on Progressive Familial Intrahepatic Cholestasis